Clinical Trial Update: Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma [Phase 2]

View source ↗

Summary

This document outlines a Phase 2 clinical trial testing a triple combination of zanubrutinib, obinutuzumab, and lenalidomide (ZGR) for untreated follicular lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Follicular Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING